R-CHOP方案初治CD20阳性弥漫大B细胞淋巴瘤的临床疗效评价  

Therapeutic Effect Evaluation of the Combination Regimen of Rituximab and CHOP for CD20 Positive Diffuse Large B-cell Lymphoma

作　　者：刘爱学[1] 张容榕[1] 李明淑[1] 周泽强[1] 冯天举[1] 

机构地区：[1]深圳市第二人民医院肿瘤科,广东深圳518000

出　　处：《肿瘤预防与治疗》2012年第4期246-248,共3页Journal of Cancer Control And Treatment

摘　　要：目的:观察利妥昔单抗联合CHOP方案(R-CHOP方案)初治弥漫大B细胞淋巴瘤的疗效及不良反应。方法:对20例初治弥漫大B细胞淋巴瘤患者,给予6周期～8周期R-CHOP方案治疗。利妥昔单抗375mg/m^2,静滴,d1;环磷酰胺750mg/m^2,iv,d1;阿霉素50mg/m^2,iv,d1;长春新碱1.4mg/m^2,iv,d1;强的松100mg/d,口服,d1-5;21天为一周期。结果:20例患者中,完全缓解13例,部分缓解3例,稳定1例,进展3例,客观缓解率80%。主要毒副反应为血液学毒性,轻度胃肠道反应,无利妥昔单抗不良反应。结论:R-CHOP方案初治CD20阳性弥漫大B细胞淋巴瘤缓解率高,毒副反应可以耐受。Objective： To observe the effect and toxicity of combination treatment of rituximab and CHOP-regimen for diffuse large B eel1 lymphoma（DLBCL）. Methods： 20 patients initially diagnosed as DLBCL received R-CHOP regimen of 6 -8 cycles： rit- uximab 375mg/m2 intravenously infused on day1, cyclophosphamide 750mg/m2 on dayl, adriamycin 50mg/m2 on dayl and vincristine 1.4mg/m2 on day 1, prednisone 100mg/d taken orally on day 1 - 5 ; 21days as one cycle. Results： In all 20 patients, 13 got complete response and 3 partial response, 1 SD, 3 PD. The overall response rate was 80. 0%. Main toxicity included myelosuppression, slightly gastrointestinal reaction. No rituximab related toxicity was observed in all the patients. Conclusion： R-CHOP regimen has high efficacy with mild toxicity in the treatment of initially diagnosed diffuse large B cell lymphoma.

关 键 词：利妥昔单抗 弥漫性大B细胞淋巴瘤 CHOP方案 

分 类 号：R733.1[医药卫生—肿瘤]